The purpose of this study is to determine the highest dose of a new drug called PF-02341066 (crizotinib) that can be given safely to people with advanced cancer. This drug helps stop blood vessels from feeding tumors, causing cancer cells to starve or die. Researchers hope the study will indicate what effect this drug has on patients and their cancer cells. PF-02341066 is taken orally (by mouth).
Researchers also want to see how this drug might work with or against other common drugs. Some patients may receive a drug called midazolam, a sedative used to help with anesthesia. This drug will be given at a low dose and should not have any effect on patients. Midazolam is being used because it is similar to many kinds of drugs that interact with PF-02341066. Researchers will test patients’ blood to see how much of PF-02341066 (or midazolam) stays in the system while taking PF-02341066.